Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma

Amber M. Johnson,Bonnie L. Bullock,Alexander J. Neuwelt,Joanna M. Poczobutt,Rachael E. Kaspar,Howard Y. Li,Jeff W. Kwak,Katharina Hopp,Mary C. M. Weiser-Evans,Lynn E. Heasley,Erin L. Schenk,Eric T. Clambey,Raphael A. Nemenoff
DOI: https://doi.org/10.4049/jimmunol.1900778
2020-03-16
The Journal of Immunology
Abstract:Key Points<p><li><p>Expression of csMHCII is a determinant of the composition of the TME.</p></li><li><p>csMHCII is a factor determining the response to anti–PD-1 therapy.</p></li></p>
What problem does this paper attempt to address?